Diltiazem in Jervell and Lange-Nielsen Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

October 23, 2024

Study Completion Date

October 23, 2024

Conditions
Jervell and Lange Nielsen Syndrome
Interventions
DRUG

diltiazem

IV diltiazem (0.25 mg/kg) will be given over 2 minutes, with ECG and blood pressure measurements at baseline, 2, 5, 7, 10, 15 and 20 minutes. If at 10 minutes there is no QT shortening, and blood pressure is stable, an additional dose (0.35 mg/kg) will be given with ECG and blood pressure measurements at 17, 20, 22, 25, 30 and 35 minutes.

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt University Medical Center

OTHER

NCT06534671 - Diltiazem in Jervell and Lange-Nielsen Syndrome | Biotech Hunter | Biotech Hunter